JA-SAFE (Joint Action on Health Promotion and Disease Prevention including Smoke- and Aerosol-Free Environments) is a collaborative project funded by the European Union that aimsto reduce the burden of non-communicable diseases, especially heart disease, and the risk factors associated with them. The project focuses on reducing the use of tobacco and nicotine products, reducing exposure to tobacco smoke and aerosols,and preventing alcohol-related harm at the individual level.
JA-SAFE supports the goal of a tobacco-free generation by 2040 in the EU's Beating Cancer Plan and the Safe Hearts Plan. The project produces and disseminates evidence-based approaches and good practices, strengthens the competence of the Member States and promotes the development ofnational policies.
More than 60 organisations from 23 European countries are involved in the project, including public health institutions, ministers, research institutes and universities, as well as stakeholders. The project is coordinated by the National and Kapodistrian University of Athens (UOA) in Greece.
Goals
The main objective of the JASAFE project is to support the prevention of non-communicable diseases and health promotion in Europe by strengthening measures to prevent and reduce the harmful effects of tobacco, nicotine and alcohol.
The key objectives are:
- promote the introduction and implementation of smoke- and aerosol-free environments (SAFE) in EU countries
- discourage the initiation of tobacco and nicotine products and support the goal of a tobacco-free generation in the EU
- to develop and expand effective tobacco and nicotine cessation practices in social welfare and health care services
- prevent alcohol-related harm, especially for children and young people.
Implementation
JA-SAFE is implemented in 2025–2029 as a European cooperation project divided into five thematic areas. These include smoke- and aerosol-free environments, smoking and nicotine cessation, reducing alcohol-free harm, promoting a tobacco-free generation, and supporting health promotion.
The project will produce and promote tools, guidelines and good practices to support decision-making and practical implementation, strengthen the exchange of information between Member States and support the implementation of national measures. The project will utilise research data, expert cooperation and stakeholder involvement.
JA-SAFE works in close cooperation with EU institutions, national authorities and international networks and disseminates the results widely to professionals, decision-makers and citizens.
Funding
This project is co-funded by the European Union's EU4Health programme (2021–2027) under grant agreement 101233428.
Partners
- Agostino Gemelli University Hospital Foundation IRCCS (FPG) – Italy
- Aarhus Municipality – Denmark
- Barcelona Clinical Research Foundation – August Pi i Sunyer Biomedical Research Institute (IDIBAPS CERCA) – Spain
- Barcelona Public Health Agency (ASPB) – Spain
- Cancer Society of Finland, CSF – Finland
- Cantabrian Health Service (SCS) – Spain
- Carol Davila University of Medicine and Pharmacy Bucharest (CDU) – Romania
- Catalan Institute of Oncology (ICO) – Spain
- Centre for Disease Prevention and Control (SPKC) – Latvia
- Croatian Institute of Public Health (CIPH) – Croatia
- Cyprus National Addictions Authority (NAAC) – Cyprus
- Department of Health – Government of Catalonia (GENCAT) – Spain
- Federal Ministry of Health (FMZ) – Bosnia and Herzegovina
- Filha ry (Finnish Lung Health Association, FLHA) – Finland
- Finnish Institute for Health and Welfare (THL) – Finland
- Galician Public Foundation – Health Research Institute of Santiago de Compostela (IDIS) – Spain
- Gottsegen National Cardiovascular Center (GOKVI) – Hungary
- Health Department of Galicia (CSG) – Spain
- Institute for Addictive Behaviours and Addictions, IP (ICAD) – Portugal
- Italian National Institute of Health (ISS) – Italy
- Liguria Region – Italy
- Lithuanian University of Health Sciences (LSMU) – Lithuania
- Lombardy Region – Italy
- Local Health Authority ULSS 6 Euganea (ULSS 6) – Italy
- Mario Negri Institute for Pharmacological Research (IRFMN) – Italy
- Marqués de Valdecilla University Hospital and Health Research Institute (IDIVAL) – Spain
- Marius Nasta Institute of Pneumophysiology (IPMN) – Romania
- Ministry of Health and Access to Care – France
- Ministry of Health and Social Security – Luxembourg
- Ministry of Health – Latvia
- Ministry of Health of the Republic of Lithuania (SAM LT) – Lithuania
- National and Kapodistrian University of Athens (UOA) – Greece
- National Cancer Institute (NVI) – Lithuania
- National Directorate General for Hospitals (OKFŐ) – Hungary
- National Institute for Health Development (TAI) – Estonia
- National Institute of Public Health (INSP) – Romania
- National Institute of Public Health (SZU) – Czech Republic
- National Institute for Public Health and the Environment (RIVM) – Netherlands
- National Korányi Institute of Pulmonology (NKIP) – Hungary
- National Public Health and Pharmaceutical Centre (NNGYK) – Hungary
- National Public Health Institute (NIJZ) – Slovenia
- National Public Health Organization (NPHO) – Greece
- North Buda Saint John Central Hospital (ÉBSZJCK) – Hungary
- Pauls Stradiņš Clinical University Hospital (PSCUH) – Latvia
- Pharmaceutical Society of the Republic of Srpska (PSRS) – Bosnia and Herzegovina
- Region of Skåne – Sweden
- Region of Southern Denmark – Denmark
- Region Zealand – Denmark
- Research Institute of the Hospital de la Santa Creu i Sant Pau Foundation, Barcelona (IRSANTPAU CERCA) – Spain
- Riga Stradiņš University (RSU) – Latvia
- Sciensano – Belgium
- Semmelweis University – Hungary
- State Institution Public Health Center of the Ministry of Health of Ukraine (PHC) – Hungary
- TobaccoFree Research Institute (TFRI) – Ireland
- University of Banja Luka (UNIBL) – Bosnia and Herzegovina
- University of Cyprus (UCY) – Cyprus
- University of Santiago de Compostela (USC) – Spain
- Vallensbæk Municipality – Denmark
- Vilnius University (VU) – Lithuania
Contact details
Updated: